Bright Minds Biosciences is a biotechnology company. Co. is creating chemical entities as targeted therapeutic agents for treatment of disorders where a serotonin (5-HT) receptor (either 5-HT2A, 5-HT2C or 5-HT2A/C) driven mechanism is the underlying pathology. These targeted neurocircuit disorders include neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders. Examples of these diseases include 5-HT2C disorders like pediatric epilepsies, Alzheimer's disease psychosis and dementia, 5-HT2A receptor disorders like depression and post-traumatic stress disorder, and 5-HT2A/C neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. The DRUG YTD return is shown above.
The YTD Return on the DRUG YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether DRUG YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DRUG YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|